- Home
- ARCB vs NAMS Comparison
ARCB vs NAMS Comparison
Compare ARCB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCB
- NAMS
- Stock Information
- Founded
- ARCB 1923
- NAMS 2019
- Country
- ARCB United States
- NAMS Netherlands
- Employees
- ARCB N/A
- NAMS N/A
- Industry
- ARCB Trucking Freight/Courier Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCB Industrials
- NAMS Health Care
- Exchange
- ARCB Nasdaq
- NAMS Nasdaq
- Market Cap
- ARCB 2.4B
- NAMS 2.3B
- IPO Year
- ARCB N/A
- NAMS N/A
- Fundamental
- Price
- ARCB $108.39
- NAMS $24.90
- Analyst Decision
- ARCB Buy
- NAMS Strong Buy
- Analyst Count
- ARCB 14
- NAMS 6
- Target Price
- ARCB $130.69
- NAMS $33.80
- AVG Volume (30 Days)
- ARCB 313.4K
- NAMS 419.7K
- Earning Date
- ARCB 11-01-2024
- NAMS 11-06-2024
- Dividend Yield
- ARCB 0.44%
- NAMS N/A
- EPS Growth
- ARCB 8.96
- NAMS N/A
- EPS
- ARCB 8.07
- NAMS N/A
- Revenue
- ARCB $4,266,908,999.00
- NAMS $33,594,000.00
- Revenue This Year
- ARCB N/A
- NAMS N/A
- Revenue Next Year
- ARCB $4.30
- NAMS N/A
- P/E Ratio
- ARCB $13.48
- NAMS N/A
- Revenue Growth
- ARCB N/A
- NAMS 78.77
- 52 Week Low
- ARCB $94.77
- NAMS $8.90
- 52 Week High
- ARCB $153.60
- NAMS $26.35
- Technical
- Relative Strength Index (RSI)
- ARCB 49.64
- NAMS 78.93
- Support Level
- ARCB $112.31
- NAMS $24.23
- Resistance Level
- ARCB $122.10
- NAMS $19.30
- Average True Range (ATR)
- ARCB 5.02
- NAMS 1.27
- MACD
- ARCB 0.34
- NAMS 0.52
- Stochastic Oscillator
- ARCB 40.40
- NAMS 96.99
About ARCB ArcBest Corporation
ArcBest Corp is engaged in logistics operations. The company operates in two operating segments, The Asset-Based segment includes the results of operations of ABF Freight System, Inc. and certain other subsidiaries. The segment operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed LTL services. The services including freight transportation related to managed transportation solutions and other services. The Asset-Light segment includes the results of operations of the Company's service offerings in truckload, ground expedite, dedicated, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.